Current price is more than the intrinsic value

Intrinsic Value

Stock has not been able to generate better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

YES Securities is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 500 in its research report date May 17, 2022.

Buy Indoco Remedies; target of Rs 500: YES Securities

ICICI Direct is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 510 in its research report dated May 18, 2022.

Buy Indoco Remedies; target of Rs 510: ICICI Direct

Indoco Remedies Q4 Review - Growth Expectation Intact: Yes Securities

Indoco Remedies Q4 Review - Strong Revenue Guidance For U.S., Europe Markets: Prabhudas Lilladher

Indoco Remedies Consolidated March 2022 Net Sales at Rs 409.13 crore, up 34.08% Y-o-Y

Indoco Remedies Standalone March 2022 Net Sales at Rs 408.88 crore, up 34.12% Y-o-Y

Net Sales are expected to increase by 28.9 percent Y-o-Y (up 9.9 percent Q-o-Q) to Rs 393.4 crore, according to Prabhudas Lilladher.

Indoco Remedies Q4 PAT seen up 52.9% YoY to Rs 38.2 cr: Prabhudas Lilladher

Indoco Remedies receives USFDA approval for Lacosamide Injection

Pharmaceuticals firm Indoco Remedies Ltd on Tuesday said it has received final approval from the US health regulator for its generic Lacosamide tablet indicated for prevention and control of seizures.

Indoco Remedies gets final nod from US FDA for Lacosamide tablet

The approval granted by the US Food & Drug Administration (USFDA) for Lacosamide tablets is for strengths of 50 mg, 100 mg, 150 mg and 200 mg. These are the generic version of Vimpat Tablets of UCB Inc, the company said in a regulatory filing.

Indoco Remedies gets final USFDA nod for Lacosamide tablet

Indoco Remedies receives USFDA approval for Lacosamide Tablets

Indoco Remedies Limited is engaged in the manufacture of pharmaceutical products. The Company primarily manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).

Indoco Remedies Ltd

Indoco Remedies Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Buy Indoco Remedies; target of Rs 500: YES Securities

Buy Indoco Remedies; target of Rs 510: ICICI Direct

Indoco Remedies Q4 Review - Growth Expectation Intact: Yes Securities

Indoco Remedies Q4 Review - Strong Revenue Guidance For U.S., Europe Markets: Prabhudas Lilladher

Indoco Remedies Consolidated March 2022 Net Sales at Rs 409.13 crore, up 34.08% Y-o-Y

Indoco Remedies Standalone March 2022 Net Sales at Rs 408.88 crore, up 34.12% Y-o-Y

Indoco Remedies Q4 PAT seen up 52.9% YoY to Rs 38.2 cr: Prabhudas Lilladher

Indoco Remedies Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Buy Indoco Remedies; target of Rs 500: YES Securities

Buy Indoco Remedies; target of Rs 510: ICICI Direct

Indoco Remedies Q4 Review - Growth Expectation Intact: Yes Securities

Indoco Remedies Q4 Review - Strong Revenue Guidance For U.S., Europe Markets: Prabhudas Lilladher

Indoco Remedies Consolidated March 2022 Net Sales at Rs 409.13 crore, up 34.08% Y-o-Y

Indoco Remedies Standalone March 2022 Net Sales at Rs 408.88 crore, up 34.12% Y-o-Y

Indoco Remedies Q4 PAT seen up 52.9% YoY to Rs 38.2 cr: Prabhudas Lilladher

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock